STARD3 and neoplasm: Of relevance are the percentages of some tumor types in which STARD3 is overexpressed: breast cancer (123 out of 883 samples; 13.9%), large intestine cancer (25 out of 182 samples; 13.7%), liver cancer (29 out of 224 samples; 12.9%), pancreatic cancer (15 out of 109 samples; 13.76%), upper aerodigestive tract cancer (20 out of 118 samples; 16.9%), urinary tract cancer (35 out of 303 samples; 11.5%) (Figure 5).